BeOne Medicines AG/$ONC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BeOne Medicines AG
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
Ticker
$ONC
Sector
Primary listing
Employees
12,000
Headquarters
Basel, Switzerland
Website
ONC Metrics
BasicAdvanced
$34B
122.38
$2.47
0.52
-
Price and volume
Market cap
$34B
Beta
0.52
52-week high
$385.22
52-week low
$196.45
Average daily volume
274K
Financial strength
Current ratio
3.409
Quick ratio
2.972
Long term debt to equity
23.27
Total debt to equity
23.37
Interest coverage (TTM)
7.68%
Profitability
EBITDA (TTM)
578.818
Gross margin (TTM)
87.49%
Net profit margin (TTM)
5.37%
Operating margin (TTM)
8.37%
Effective tax rate (TTM)
31.17%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
3.96%
Return on equity (TTM)
7.46%
Valuation
Price to earnings (TTM)
122.385
Price to revenue (TTM)
6.17
Price to book
7.68
Price to tangible book (TTM)
7.8
Price to free cash flow (TTM)
38.288
Free cash flow yield (TTM)
2.61%
Free cash flow per share (TTM)
7.895
Growth
Revenue change (TTM)
40.23%
Earnings per share change (TTM)
-140.33%
3-year revenue growth (CAGR)
55.69%
10-year revenue growth (CAGR)
89.78%
3-year earnings per share growth (CAGR)
-49.72%
10-year earnings per share growth (CAGR)
-9.51%
ONC News
AllArticlesVideos
BeOne Medicines to Present at Upcoming Investor Conferences
Business Wire·3 weeks ago
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
Business Wire·4 weeks ago
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BeOne Medicines AG stock?
BeOne Medicines AG (ONC) has a market cap of $34B as of March 10, 2026.
What is the P/E ratio for BeOne Medicines AG stock?
The price to earnings (P/E) ratio for BeOne Medicines AG (ONC) stock is 122.38 as of March 10, 2026.
Does BeOne Medicines AG stock pay dividends?
No, BeOne Medicines AG (ONC) stock does not pay dividends to its shareholders as of March 10, 2026.
When is the next BeOne Medicines AG dividend payment date?
BeOne Medicines AG (ONC) stock does not pay dividends to its shareholders.
What is the beta indicator for BeOne Medicines AG?
BeOne Medicines AG (ONC) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.